LabHealth
Eight-year study finds distinct molecular paths in healthy aging
King's College London tracked 335 people and found some molecular changes moved in opposite directions.
Written by AI1 source2 min
Loading…
Diagnostics, prosthetics, vaccines, genomics: the medicine that adds years to a life.
Medicine that wins years of life: AI-assisted screening examining millions of patients, next-generation vaccines, genomics moving from sequencing to treatment, prosthetics and implants restoring lost abilities. The section follows completed clinical trials, market authorisations, hospital roll-outs — the moment a technology stops being a paper and becomes care.
The numbers rule: cohorts, detection rates, avoided mortality, costs. We gladly cover the health systems deploying at scale — India, Brazil, Southeast Asia — because frugal technologies often prove themselves there before arriving anywhere else. Every article rests on the trial, authorisation or study behind it, and cites them.
King's College London tracked 335 people and found some molecular changes moved in opposite directions.
Regorafenib, selinexor and ixazomib made up the tested three-drug combination.
The method distinguishes activated and quiescent immune cells without labels or destroying the sample.
Antisense RNA delivered with nanoparticles blocked Smyca's activity in tumors and improved responses to existing treatments.
In mice, galectin-1 strengthened lung immunity when added to an experimental nasal flu vaccine.
Gladstone, UCSF and Stanford switched off nearly 12,800 genes in human T cells from blood donors.
The result was seen in allergen-exposed mice, not people, during a puberty-timed experiment.
A Cornell team activated macrophages after targeted therapy to recruit immune cells against resistant melanoma cells.
The result is limited to cell cultures; mouse tests of tumor injections are being pursued.
About 5% of clear cell ovarian cancers showed high IL-17 activity.